Subtype-specific screen-detected and interval breast cancer rates in population screening: a BreastScreen Queensland cohort study.

Naomi Noguchi, Nick Ormiston-Smith, Michael Luke Marinovich, Julie Moore, Nehmat Houssami

Abstract read

In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Naomi NoguchiSchool of Public Health, Faculty of Medicine and Health, University of Sydney, 301C Edward Ford Building, NSW, 2066, Australia. Electronic address: naomi.noguchi@sydney.edu.au.

Nick Ormiston-SmithBreastScreen Queensland, Clinical Support Queensland, Queensland Health, 15 Butterfield Street, Herston, QLD, 4006, Australia. Electronic address: Nick.Ormiston-Smith@health.qld.gov.au.

Michael Luke MarinovichThe Daffodil Centre, University of Sydney, and Cancer Council NSW, 1 King Street, Newtown, NSW, 2042, Australia. Electronic address: luke.marinovich@sydney.edu.au.

Julie MooreQueensland Cancer Register, Cancer Alliance Queensland, Metro South Health, Burke Street Centre, 2 Burke Street, Woolloongabba, QLD, 4102, Australia. Electronic address: julie.moore2@health.qld.gov.au.

Nehmat HoussamiSchool of Public Health, Faculty of Medicine and Health, University of Sydney, 301C Edward Ford Building, NSW, 2066, Australia; The Daffodil Centre, University of Sydney, and Cancer Council NSW, 1 King Street, Newtown, NSW, 2042, Australia. Electronic address: nehmat.houssami@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo quantify subtype-specific rates of screen-detected and interval breast cancers based on hormone receptor and HER-2 status in population-based breast cancer screening participants.

methodsClinical and administrative data collected by BreastScreen Queensland (a biennial screening program) for consecutive mammography screens between 2017 and 2020 were analysed. Invasive cancer diagnosis and hormone receptors and HER-2 status were determined using BreastScreen Queensland Register and data linkage with the Queensland Cancer Register. Screen-detected and interval cancer rates for each subtype were determined overall and by age group.

resultsAmongst 971,231 screening episodes in 557,110 women, 5635 screen-detected and 1702 interval cancers were diagnosed. Overall, cancer detection rate (CDR) at screening was 58.0 per 10,000 screens and interval cancer rate (ICR) was 17.5 per 10,000 screens. Hormone receptor (ER and/or PR) positive (HER-2 negative) CDR was 47.5 per 10,000, HER-2 positive (ER, PR any) CDR was 6.1 per 10,000, and triple-negative (ER, PR and HER-2 negative) CDR was 3.7 per 10,000 screens. Hormone receptor positive ICR was 12.0 per 10,000, HER-2 positive ICR was 2.5 per 10,000, and triple-negative ICR was 2.3 per 10,000 screens. Hormone receptor positive screen-detected cancers were particularly overrepresented in older age groups and overrepresentation of triple-negative interval cancers was constant across all age groups.

conclusionsTo our knowledge, we report the world's first population-based estimates of both subtype-specific screen-detected and interval cancer rates respectively. These data provide a benchmark for investigating effects of new early detection strategies for breast cancer screening including those related to risk-based interventions.

Indexed as

Breast cancerEpidemiologyPopulation screening

Identifiers

PMID42822240

DOI10.1016/j.breast.2026.104938

PMCPMC13657236

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.